



Empowering Primary Care Management of Alzheimer's Disease (AD) Post Diagnosis: Person-centered care in a changing landscape

AAPA Conference
May 19, 2024

Theresa Sivers-Teixeira, MSPA, PA-C
Department of Family Medicine
Keck School of Medicine of University of Southern California
siverste@med.usc.edu

Disclosure

- I have no conflicts to disclose.
- For this presentation I have drawn on my research supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1QHP28740, Geriatrics Workforce Enhancement Program for \$3.5 million. This information or content and conclusions are those of the author and should not be construed as the official position or policy or, nor should any endorsements be inferred by, HRSA, HHS or the U.S. Government.

Objectives

- Explain the imperative for primary care PAs to manage post-diagnosis Alzheimer's disease across the spectrum of disease burden.
- Identify goals of primary care management of Alzheimer's disease and major components of clinical care
- Describe person-centered approach to primary care management of Alzheimer's disease.
- Recognize appropriate candidates for recent pharmaceutical interventions and summarize potential benefits and risks associated with these therapies

Why is this topic important to primary care?

- Aging #1 risk factor for Alzheimer's Disease
- People living with Alzheimer's Disease (PwD) are hospitalized more than older adults without AD
- 95 % of persons living with dementia (PwD) have at least 1 chronic disease and acquire more with AD progression
- **Emerging biomarker detection & new treatments** – PAs will need to know which patient may qualify as well as risks & benefits of treatment
- Most primary care PAs do not feel comfortable managing or co-managing AD or related dementias

Goals of Person-centered Primary Care of PwD

- Whole person approach- treating the person not a disease
- Chronic disease management
- Evidence-based medicine guided by what is/has been most important to the patient
- Enhance and maintain quality of life throughout disease progression
- Strengths based approach-adaptations to preserve autonomy and dignity

Aligned with Age-Friendly Care (4 M's)

- What Matters most to PwD*
 - Know and respect cultural values and norms
- Medications
 - Reduce polypharmacy, deprescribe high risk medications, ask about side effects
- Mobility
 - Optimize functional mobility, reduce fall risk
- Mentation (3 D's)
 - Detecting & Managing depression, delirium, dementia

Components of managing AD in Primary Care

- Optimize Function & Quality of Life
- Manage Chronic Disease
- Promote Positive Behavioral Health
- Optimize Medication Therapy
- Assess Safety & Driving
- Assess for Elder Mistreatment (EM) & be alert to risk for EM (mandated reporter)
- Facilitate Advanced Care Planning & End of Life Care
- Assess Care Partner Needs
- Refer to Community Services and Supports

Timing & Teams

You can't do it all at once!

You can't do it all alone!

Optimize Function & Quality of Life

Know What Matters to the PwD

- What gives your life meaning/purpose?
- What brings you pleasure?
- Current and past values?
- Who are the people in your life you most trust?

Assess ADL & IADLs

- Functional Assessment Questionnaire ([FAQ](#))
- AD8 brief informant assessment ([AD8](#)) by trusted person often identified as CG)

Assess mobility

- Ask about falls/near falls in last 2 month
- Timed Up & Go ([TUG](#))

Promote Positive Behavioral Health

Screen for depression & anxiety

- Geriatric Depression Scale ([GDS](#))
- Tell me about your mood? Changes?
- Ask key trusted informant about mood?*
- Social isolation?

Observations (*changes*)

- Apathy
- Engagement
- Body language

Agitation/behavior changes

- *Rule out delirium first!*
- Caregiver Coaching ([Caregiver Tip Sheets](#))
- Caregiver support
- Medication- consider with caution only after other options failed

Medication Management

- Reduce polypharmacy
- Ask about side effects (risk vs benefits)
- Deprescribe high risk medication for patients with AD ([Current Beers Criteria](#))
 - Avoid anticholinergics, muscle relaxants, opioids, hypnotics, antipsychotics....
- Simplify when possible- educate on tools to organize medications
- When starting medications start low and go slow

Medication for AD

Cholinesterase inhibitors for *mild to moderate dementia*

*Does not reverse cognitive decline

* Discontinue if no reduction of sx or GI distress (shared decision making)

- **Donepezil (Aricept)**

- 5 mg, 10 mg tab PO daily
- Start at 5mg x 4 weeks, can increase to 10 mg

- **Galantamine**

- Extended release 8 mg, 16 mg 24 mg tab or liquid 4 mg/mL
- Start 4 mg PO bid, can increase to 8 mgx in PO bid
- If is interrupted by > 3 days retitrate to from 4 mg

- **Rivastigmine**

- 1.5 mg, 3 mg, 4.4 mg, 6 mg tab
- Start 1.5 mg bid for 2 weeks and increase by 1.5 mg/dose q 2 weeks
- Rivastigmine transdermal (Exelon)
 - May use if other options cause GI distress, not covered by all insurers

Medication for AD

- Glutamate blocker
- May help slow decline in memory & thinking skills.
 - Memantine:
 - In liquid or tab form taken 1-2 times daily
 - Start at 5 mg PO daily and titrate up to 20 mg
 - Increase by 5 mg/day no more frequently than q wk
 - Max dose 10 mg bid

Side effects may include dizziness, headache, confusion, hallucinations, agitation & constipation.

Advanced Care Planning/End of Life Care

- **Anticipatory guidance** on disease progression
 - Overtime decreasing function will require more care
 - **Identify trusted people** to help you
 - **Legal/Financial matters-** appointment of trusted people to manage finances & medical decision making when needed when unable to make a decision for self
 - **Advanced Care Plan for Healthcare**
 - Consider **POLST** when disease is more severe
 - **Consider Hospice for end stage dementia-** more resources, often unable to leave home

Assess Safety

Still driving?



- Ask if still driving-recent hx of accidents?, lost?
- Consider OT specialty referral to assess driving
- Resource for PwD &
 - [Family Conversations About Alzheimer's Disease, Dementia & Driving](#)

Home Safety



- Home environment- adaptations as disease progresses:
 - Fall risk, supervision at home need, ability to be on own, Has the stove ever been left on?

Safety- Elder Mistreatment



- **50% of PwD experience mistreatment**, most often by a trusted person
- **Types of mistreatment:** financial*, emotional*, physical, sexual, neglect, medication misuse
- **Increased risk with:**
 - PwD increased dependence, social isolation
 - CG overwhelmed, financially dependent on PwD, substance misuse, social isolation

What you can do:




Screen patient *without* CG present

- Screens on PwD are sensitive and specific
 - Not delirious, able to respond

Educate yourself and caregivers preventing abuse & detecting suspected abuse

- [National Center on Elder Mistreatment](#) (brief practical education, multiple languages)
- Always keep elder mistreatment on your differential
- Report suspected mistreatment to Adult Protective Services



Elder Mistreatment Screening & Response Tool (EMSART)

- Brief Screen (Yes or No)
 - Has anyone close to you harmed you?
 - Has someone failed to give you the care that you need?
 - Has anyone forced you to sign papers or used your money against your will?

*If any positive there is a more in depth screening in link



National Collaboratory to Address
Elder Mistreatment

[Link to NACEM](#)

Caregiver/Trusted Other



Must also maintain & preserve quality of life

- Encourage all to participate in CG Support group & CG Education (available remotely)
- CG Burden Screening
 - Positive
 - Refer to Social Work, advise to discuss with own PCP, Respite Care, Community Resources, Encourage self care, Other caregivers: paid or unpaid
 - Private Geriatric Care Managers for those that can afford service

Team-Based Care Primary Care

- Interprofessional Referrals



- **Behavioral health-** caregiver burden, family conferences, advanced care directives, depression
- **PT-** optimize physical function, reduce fall risk,
- **OT-** driving assessment, adapting meaningful activities, modification of activities to maintain sense of purpose, home modification “dementia friendly”
- **Social work-** community referrals, social intake, help with completing forms for resources,
- **Community Health Worker** Programs
- **Specialists-** Geriatrician, Gero-psychologist, Memory Neurology, Gero-pharmacist * *complex cases, unusual progression*

Effective Referrals



- Why are you referring? Dx, data
- What question/concern do you have?
- Any previous work up?
- What have you tried?
- Include problem with dx code in note with plan
- *A warm hand off increases effectiveness of referral (call, note via email, EHR message)*

Educate Your Clinical Team



Effective communication with PwD & CG

Front office, scheduler, follow up, reminder calls, referrals

- Who to contact for appts/reminders
- Remind to bring trusted family or friend with them

Clinical teammates: MA, LVN, Care Manager...

- Huddle to identify PwD on schedule
- Educate in effective screening
 - CG & informant screens can be done by phone or while waiting, already connected with any community resources?
 - TUG, fall screen, GDS can be done before seen by you
 - Education & warm hand off to community resources & referrals can be done post visit in person or in follow up call

How to manage:

- If possible, schedule multiple appointments out as far as template allows.
- As disease progresses continue to cover primary care components. Needs and care plan will change as more chronic issues related to the disease emerge

Disease Progression Needs Shift in Plan

- What worked 6 months ago may not work now
 - Reduced function > increased dependence
 - Increased caregiver burden > burnout, PwD safety
 - Increased safety risks
 - Behavioral changes

Like any other chronic disease when uncontrolled, adapt your plan. Consider appropriate referrals

What to know about monoclonal antibody treatment for AD?

~~aducanumab~~, lecanemab, donanemab

Goal: slow progress of AD by reducing specific beta amyloid proteins

- Efficacy- *small* effects cognitive scores or changes in function in studies *so far*
- Biomarkers
 - *Large* effects on multiple biomarkers
 - Amyloids dramatically reduced on PET scans

Adverse Events

- Adverse Events that generally resolve early in treatment:
 - Infusion reactions at site,
 - cerebral edema on imaging (mostly without sx),
 - Microhemorrhages on imaging

Black Box Warning

- Amyloid-Related Imaging Abnormalities (ARIA)
 - Usually early in treatment & then resolves
- ***Homozygous APOE E4 carriers*** have a higher risk of intracerebral hemorrhages some of which have been fatal have occurred in this group. Rare.

15% of AD patients

Challenges

- Complex procedures
- Barriers to access
- Threats to effective treatment
 - Missed doses, non-compliance, drop out, infusion visits, lack of assessments, extra MRIs
- Small clinical effects
- Benefit considerations rely on plaque reduction & clinical management

More trials needed. Now recruiting people without cognitive impairment biomarker +

Would I qualify for lecanemab?

- Early AD?
 - Mild impairment
 - MRI scan < 4 microhemorrhages
 - PET scans
 - General good health? Ambulatory?
 - 55-80
- Living at home? Partner?
- Twice monthly infusion visits?
- Travel, time, effort, commitment?
- Can I afford this?
- Insurance Copays? Medicare? Medicare Advantage?

USC

A few words about serum biomarkers

- AD dx could only be confirmed with a PET scan or CSF (lumbar puncture) that demonstrated a high level of specific amyloid proteins consistent with AD pathology
- NEW blood based biomarkers
 - Identify these beta amyloids 40/42 and phosphorylated tau proteins p181 & p231
 - Not all people who are found to have these markers develop AD
 - Amyloid ratio, combined with a person's age and APOE phenotype may indicate a amyloid probability score low, intermediate, or high consistent with AD

Debate whether they should be used in primary care

- Larger studies are needed especially in diverse populations
- Global Alzheimer's Association working group and American Geriatric Society advise against use of these test in primary care
- Suggest cautious initial use in specialized memory clinics
 - If you have a high risk patient family hx, known APOE E4 risk the recommendation is to refer to a memory clinic

Thank you!

Feel free to contact me for more resources or any other information or encouragement you might need.

Theresa Sivers-Teixeira
siverste@med.usc.edu

Resources

- National Resources
 - <https://www.alz.org/help-support/i-have-alz/know-what-to-expect/just-diagnosed>
- ACT on Alzheimer's Clinical Provider Practice Tool
 - <https://actonalz.org/sites/default/files/documents/ACTNAT-Provider-ClinicalPracticeTool.pdf>
- Video Tutorials
 - <https://actonalz.org/sites/default/files/documents/ACTNAT-Provider-ClinicalPracticeTool.pdf>
- After a Diagnosis
 - <https://static1.squarespace.com/static/559c4229e4b0482682e8df9b/t/561f2778e4b05fb7f59240d4/1444882296205/DFA-Tools-AfterDiagnosis.pdf>
- EHR Decision Support Tools for Alzheimer's and Related Dementias
 - <https://static1.squarespace.com/static/559c4229e4b0482682e8df9b/t/57714bdcf7e0ab72f1ab3f14/1467042781285/DFA-Tools-EMRManual.pdf>
- National Institute on Aging- Alzheimer's Disease and Related Dementias: Resources for Professionals
 - <https://www.nia.nih.gov/health/alzheimers-dementia-resources-for-professionals>
- Caregiver Tips Sheets <https://www.alzheimersla.org/wp-content/uploads/2023/07/Caregiver-Tip-Sheets-all-English-Spanish-07-14-23.pdf>
- Screening, Evaluation and Management of AD and Related Dementias <https://championsforhealth.org/wp-content/uploads/2021/09/Alzheimers-Project-Booklet-vII-082221-Web.pdf>
- [Dementia Care Aware Cognitive Health Assessment](https://www.dementiacareaware.org/wp-content/uploads/2024/04/Dementia-Care-Aware-Cognitive-Health-Assessment.pdf)
<https://www.dementiacareaware.org/wp-content/uploads/2024/04/Dementia-Care-Aware-Cognitive-Health-Assessment.pdf>
- [Alzheimer's Association](#) Find state and local resources in your area